2021.10.12 · Company News

Reforgene named a 2021 Top 50 most innovative Chinese biopharma company

Reforgene named a 2021 Top 50 most innovative Chinese biopharma company

On October 11, 2021, the BPID 2021 Shanghai (Minhang) Biomedical Industry Innovation Summit was grandly held. Hosted by the Minhang District People's Government of Shanghai and the Shanghai Association for Science and Technology, the conference focused on the intelligent convergence of cutting-edge biomedical innovation technologies and the entire industry chain, covering hot topics such as the transformation and layout of the biomedical and smart healthcare industries, investment strategies for innovative biological drugs, the international vision of innovative biological drugs, and innovative technologies and processes of biological drug CRO/CDMO.

At the awards ceremony, the conference unveiled the list of winners of the 2021 Third Star List. The list is hosted by the well-known biomedical industry media 医麦客, and selected through the professional evaluation of the Star Research Institute with extensive solicitation of industry expert opinions. Reforgene was selected into the "2021 Top 50 Most Innovative Chinese Biopharmaceutical Enterprises", an honor that also represents the industry's high recognition of Reforgene.

Founded in 2019, Reforgene is a well-known gene drug R&D enterprise in China, driven by gene editing at its core and dedicated to the birth of curative medicines. It has established a good foundation for technology and talent development, and, relying on its independently developed core technology system, has laid out product R&D in two areas: genetic diseases and major high-incidence diseases. Reforgene has completed three rounds of financing and brought in top-tier investment institutions.

The next decade will bring a golden opportunity for the development of China's biomedicine, from following Europe and the United States in the past to gradually synchronizing, and presenting leading innovation in some directions. In recent years, the COVID-19 pandemic has also prompted countries to deeply recognize the value of biomedicine in safeguarding human health and to give unprecedented support. Against this global trend, Reforgene always upholds the lofty philosophy of serving the most fundamental needs of human life and health, providing patients with revolutionary curative medicines.

← Back to news
Reforgene Medicine

About Reforgene

Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.

Learn more →

Media Contact

info@reforgene.com · BD@reforgene.com